Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells $228,560.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph R. Young sold 5,714 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the transaction, the senior vice president now owns 53,171 shares of the company’s stock, valued at $2,126,840. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Vera Therapeutics Stock Down 1.7 %

Shares of Vera Therapeutics stock opened at $47.97 on Friday. The company has a fifty day moving average price of $43.39 and a 200 day moving average price of $25.05. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49. Vera Therapeutics, Inc. has a twelve month low of $6.05 and a twelve month high of $50.78. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -20.95 and a beta of 1.05.

Wall Street Analyst Weigh In

A number of research firms have recently commented on VERA. Oppenheimer began coverage on Vera Therapeutics in a report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price objective for the company. Wedbush upped their price objective on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a report on Thursday, March 21st. Guggenheim restated a “buy” rating and set a $56.00 price objective on shares of Vera Therapeutics in a report on Friday, April 5th. Raymond James upgraded Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $29.00 to $37.00 in a report on Friday, January 26th. Finally, Cantor Fitzgerald began coverage on Vera Therapeutics in a report on Monday, January 8th. They set an “overweight” rating for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $32.29.

Institutional Trading of Vera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Vera Therapeutics by 3.8% during the 4th quarter. Vanguard Group Inc. now owns 1,633,608 shares of the company’s stock worth $25,125,000 after purchasing an additional 59,218 shares during the period. Goldman Sachs Group Inc. boosted its position in Vera Therapeutics by 54.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 649,218 shares of the company’s stock valued at $9,985,000 after buying an additional 229,414 shares during the last quarter. GSA Capital Partners LLP boosted its position in Vera Therapeutics by 75.5% in the 4th quarter. GSA Capital Partners LLP now owns 52,590 shares of the company’s stock valued at $809,000 after buying an additional 22,620 shares during the last quarter. Virtus ETF Advisers LLC purchased a new position in Vera Therapeutics in the 4th quarter valued at about $97,000. Finally, Barclays PLC boosted its position in Vera Therapeutics by 58.6% in the 4th quarter. Barclays PLC now owns 113,747 shares of the company’s stock valued at $1,751,000 after buying an additional 42,044 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.